Health Care Innovation
Commentary
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Drug Innovation
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Commentary
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Commentary
Cutting Medical Costs Can Be a Bargain
Much of the medical progress in the past half-century has involved expensive, high-tech diagnostic tests and therapies. But it would be a mistake to gainsay the value of inexpensive, low-tech innovations. Consider the problem of falls, which are both a cause and effect of declining health in the elderly. They ...
California
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
Commentary
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Commentary
Americans Support Paying for Miracle Cures
Without pro-market payment reforms, cutting edge medical treatments known as gene therapies run the risk of becoming the dance that no one attends. Gene therapies are not medicines, instead, they are akin to an organ transplant. These procedures typically use re-engineered viruses to repair, replace, or shut off malfunctioning genes ...
Commentary
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Cutting Medical Costs Can Be a Bargain
Much of the medical progress in the past half-century has involved expensive, high-tech diagnostic tests and therapies. But it would be a mistake to gainsay the value of inexpensive, low-tech innovations. Consider the problem of falls, which are both a cause and effect of declining health in the elderly. They ...
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Americans Support Paying for Miracle Cures
Without pro-market payment reforms, cutting edge medical treatments known as gene therapies run the risk of becoming the dance that no one attends. Gene therapies are not medicines, instead, they are akin to an organ transplant. These procedures typically use re-engineered viruses to repair, replace, or shut off malfunctioning genes ...
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
